Thomas Cavanagh Director and CEO
Thomas is co-founder, CEO and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build four previous private-equity-backed ventures…
Thomas is co-founder, CEO and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build four previous private-equity-backed ventures…
Dina is a partner with NeoMed Management, and Advisor to Omega Funds. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i in London and Index Ventures in Geneva, Dina’s successful investments include Endosense, EUSA Pharma, Novexel, and Wilson Therapeutics. Dina serves …
Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …
Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina currently serves on the boards of Confo …
Dmitrij Hristodorov, PhD, is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as …
Tassos is an investment manager at IP Group and specializes in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (formerly CRT) where he led the intellectual property sourcing, licensing, and spin-out creation of CRUK-funded technologies. He has experience in technology transfer …
Ronald is co-founder, Chief Scientific Officer, and a Board Observer of Oxular. With more than 30 years of medical device and drug product development experience, Ronald has led multi-disciplinary technical teams, clinical trial development, and product registration in the US, the EU, China, and Brazil. His ophthalmic experience includes the development of novel microcatheters for …
Geert-Jan is Managing Partner at Forbion and has a leading role in the firm’s investment team and portfolio. He is an experienced life sciences investor who is led Forbion’s successful investments and served on the Boards of several Forbion portfolio companies, sometimes also in an executive capacity. In addition to his portfolio management activities, he …
A board-certified neurologist and pharmacist, Friedrich is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. For more than a decade he has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was previously a key strategic contributor for retinal …
Marc is Oxular’s Senior Medical Advisor and a practicing vitreoretinal surgeon, with more than 30 years of experience in ophthalmic drug and medical device development. Previously, he was the National Eye Institute’s representative responsible for defining the clinical trial of Foscarnet, the first approved drug to treat CMV retinitis in AIDS patients. He initiated the …